HeartBeam (NASDAQ: BEAT) announced the initiation of a pilot study evaluating its investigational on-demand 12-lead ECG ...
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc., (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced ...
Company engaging in multiple options for a constructive resolution Strategy is underpinned by a clinical study that achieved the agreed upon endpoints Company believes that labeling modifications can ...
Medical Device Network on MSN
HeartBeam commences pilot study of new 12-lead ECG patch
The study will enrol around 50 high-risk coronary artery disease patients whose resting ECGs show no signs of ischemia.
(NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, announced the initiation of a pilot study evaluating its novel on-demand ...
Twelve-lead ECGs, although standard in hospitals, can be bulky and impractical for home use. On the other hand, Apple Watch’s ECG app is easy to use, but it is limited in what it can detect because it ...
(RTTNews) - HeartBeam, Inc. (BEAT), a medical technology company, announced Wednesday that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Company's groundbreaking ...
A "quasi-standard" multilead ECG can be recorded using just the Apple Watch, a report showed. The ECG function on the Watch is designed to monitor electrical activity of the heart in the direction of ...
The lead-I electrocardiogram (ECG) devices were assessed when they were used in addition to 12‑lead ECGs. Clinical experts advised that a 12‑lead ECG would still be used after lead-I ECGs to identify ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results